SG11201706125QA - Anti-transthyretin antibodies - Google Patents

Anti-transthyretin antibodies

Info

Publication number
SG11201706125QA
SG11201706125QA SG11201706125QA SG11201706125QA SG11201706125QA SG 11201706125Q A SG11201706125Q A SG 11201706125QA SG 11201706125Q A SG11201706125Q A SG 11201706125QA SG 11201706125Q A SG11201706125Q A SG 11201706125QA SG 11201706125Q A SG11201706125Q A SG 11201706125QA
Authority
SG
Singapore
Prior art keywords
transthyretin antibodies
transthyretin
antibodies
Prior art date
Application number
SG11201706125QA
Other languages
English (en)
Inventor
Tarlochan S Nijjar
Avijit Chakrabartty
Jeffrey N Higaki
Original Assignee
Prothena Biosciences Ltd
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Univ Health Network filed Critical Prothena Biosciences Ltd
Publication of SG11201706125QA publication Critical patent/SG11201706125QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201706125QA 2015-01-28 2016-01-28 Anti-transthyretin antibodies SG11201706125QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109001P 2015-01-28 2015-01-28
US201562266557P 2015-12-11 2015-12-11
PCT/IB2016/050414 WO2016120809A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (1)

Publication Number Publication Date
SG11201706125QA true SG11201706125QA (en) 2017-08-30

Family

ID=55361912

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706125QA SG11201706125QA (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Country Status (20)

Country Link
US (1) US20160257736A1 (es)
EP (1) EP3250594B1 (es)
JP (2) JP6875280B2 (es)
KR (1) KR102619359B1 (es)
CN (1) CN107428822B (es)
AU (1) AU2016210887B2 (es)
BR (1) BR112017016324A2 (es)
CA (1) CA2974911A1 (es)
CO (1) CO2017008469A2 (es)
CU (1) CU24532B1 (es)
EA (1) EA036048B1 (es)
ES (1) ES2905311T3 (es)
MX (1) MX2017009804A (es)
MY (1) MY193674A (es)
PE (1) PE20180200A1 (es)
SA (1) SA517381991B1 (es)
SG (1) SG11201706125QA (es)
TW (2) TWI781507B (es)
WO (1) WO2016120809A1 (es)
ZA (1) ZA201705662B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI781507B (zh) * 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478715A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478714A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
AU2018338790B2 (en) 2017-09-29 2022-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus and methods of use
EP3691447A4 (en) * 2017-10-06 2021-08-11 Prothena Biosciences Limited ANTI-TRANSTHYRETINE ANTIBODIES
JP7292569B2 (ja) * 2017-10-06 2023-06-19 ノボ ノルディスク エー/エス トランスサイレチンを検出する方法
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
ES2289174T3 (es) 2001-12-28 2008-02-01 Amgen Fremont Inc. Anticuerpos contra el antigeno muc-18.
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
EP2021340B1 (en) 2006-04-21 2014-07-23 The Government Of The United States, As Represented by The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
EA018190B1 (ru) 2007-03-02 2013-06-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Улучшение производства белков
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2010030203A1 (en) * 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Also Published As

Publication number Publication date
TW201636372A (zh) 2016-10-16
CA2974911A1 (en) 2016-08-04
US20160257736A1 (en) 2016-09-08
JP2021129562A (ja) 2021-09-09
WO2016120809A1 (en) 2016-08-04
KR20170120607A (ko) 2017-10-31
TWI781507B (zh) 2022-10-21
JP7219928B2 (ja) 2023-02-09
EP3250594B1 (en) 2021-11-17
SA517381991B1 (ar) 2021-12-13
CU24532B1 (es) 2021-07-02
JP2018509889A (ja) 2018-04-12
MX2017009804A (es) 2018-08-15
PE20180200A1 (es) 2018-01-31
EA201791711A1 (ru) 2017-11-30
ZA201705662B (en) 2018-08-29
KR102619359B1 (ko) 2024-01-02
CU20170096A7 (es) 2018-03-13
EA036048B1 (ru) 2020-09-18
AU2016210887A1 (en) 2017-08-10
TW202118782A (zh) 2021-05-16
ES2905311T3 (es) 2022-04-07
TWI718121B (zh) 2021-02-11
JP6875280B2 (ja) 2021-05-26
EP3250594A1 (en) 2017-12-06
AU2016210887B2 (en) 2021-11-04
BR112017016324A2 (pt) 2018-03-27
CN107428822A (zh) 2017-12-01
MY193674A (en) 2022-10-24
CO2017008469A2 (es) 2018-01-16
CN107428822B (zh) 2021-11-23

Similar Documents

Publication Publication Date Title
HK1253507A1 (zh) 抗 ror1 抗體
HK1256116A1 (zh) 抗lag-3抗體
HK1254836A1 (zh) 抗-ror1抗體
IL253633B (en) Anti-transthyretin antibodies
GB201521391D0 (en) Antibodies
GB201521393D0 (en) Antibodies
HK1246804A1 (zh) Tau結合抗體
GB201521382D0 (en) Antibodies
ZA201705662B (en) Anti-transthyretin antibodies
IL255323A0 (en) Anti-fcrn antibodies
HK1255056A1 (zh) 抗cd115抗體
SG11201706126WA (en) Anti-transthyretin antibodies
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
IL284022A (en) Anti-transthyretin antibodies
GB201518728D0 (en) Antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201504858D0 (en) Antibodies
GB201502591D0 (en) Antibodies